VBI Vaccines Inc (NASDAQ: VBIV) today announced constructive Stage 1 data from its Stage 1/2 pilot of the paramount of its enclosed virus-like particle (eVLP) COVID-19 inoculation contenders, VBI-2902a, in healthy grownups age 18-54 years of age. The Stage 1 lot of the ongoing Phase 1/2 revision evaluated one- and […]